3 Drugs Stocks Moving The Industry Upward
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Two out of the three major indices are trading up today with the
Dow Jones Industrial Average
(
^DJI
) trading up 55 points (0.3%) at 18,183 as of Monday, March 23, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,001 issues advancing vs. 987 declining with 152 unchanged.
The Drugs industry currently sits down 0.5% versus the S&P 500, which is up 0.2%. Top gainers within the industry include
(
), up 3.1%, and
(
), up 0.7%. On the negative front, top decliners within the industry include
(
), down 5.9%,
(
), down 3.9%,
(
), down 3.4%,
(
), down 3.1% and
(
), down 1.8%.
TheStreet would like to highlight 3 stocks pushing the industry higher today:
3.
Teva Pharmaceutical Industries
(
) is one of the companies pushing the Drugs industry higher today. As of noon trading, Teva Pharmaceutical Industries is up $0.86 (1.4%) to $62.96 on average volume. Thus far, 2.4 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4.4 million shares. The stock has ranged in price between $62.01-$63.07 after having opened the day at $62.70 as compared to the previous trading day's close of $62.10.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. Teva Pharmaceutical Industries has a market cap of $52.4 billion and is part of the health care sector. Shares are up 8.0% year-to-date as of the close of trading on Friday. Currently there are 13 analysts who rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 9 rate it a hold.
TheStreet Ratings rates
Teva Pharmaceutical Industries
as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full
Teva Pharmaceutical Industries Ratings Report
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
2. As of noon trading,
(
) is up $1.06 (1.4%) to $77.18 on heavy volume. Thus far, 3.3 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $75.95-$77.46 after having opened the day at $76.02 as compared to the previous trading day's close of $76.12.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. Eli Lilly and has a market cap of $82.5 billion and is part of the health care sector. Shares are up 10.3% year-to-date as of the close of trading on Friday. Currently there are 6 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 9 rate it a hold.
TheStreet Ratings rates
Eli Lilly and
as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
1. As of noon trading,
(
) is up $0.89 (0.9%) to $103.29 on average volume. Thus far, 3.4 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 8.9 million shares. The stock has ranged in price between $102.23-$103.33 after having opened the day at $102.47 as compared to the previous trading day's close of $102.40.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Johnson & Johnson has a market cap of $282.8 billion and is part of the health care sector. Shares are down 2.1% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 7 rate it a hold.
TheStreet Ratings rates
Johnson & Johnson
as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
Johnson & Johnson Ratings Report
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
null